Cosmos Pharmaceutical

A discount store without a dispensing pharmacy enters insurance dispensing (2021)

Key decision·2021· Cosmos Pharmaceutical — the full company history →

How to lay a second pillar on top of the core strength

The character of this decision lies in connecting the company’s single greatest strength to a different kind of demand — without breaking the existing model. From its founding, Cosmos built its footfall on low-cost merchandising centred on food, and deliberately did not hold the insurance-dispensing business that requires pharmacists on staff. When it did move into dispensing, it was not to remake its format but to add a new use — the prescription — to the flow of customers it had already gathered. In the timing — unhurried, waiting to enter until the reimbursement system had been pared thin — one senses a discipline characteristic of this company.

That said, dispensing carries the heavy fixed cost of pharmacists’ wages, and could rub against the constitution of a company that has spent its life paring SG&A to the bone. How far the vision of handling dispensing at every store can coexist with low-cost management, and how far the “area-wide” separation of prescribing and dispensing (面分業) will spread, are not yet clear. As of this writing, co-located dispensing counters number just 53 stores, weighted toward the Kanto region. How thinly to lay a second pillar on top of the company’s own strength — the success or failure of this decision will be answered by the future reach and profitability of that co-located network.

Revenue and net margin, FY2016–FY2026

Revenue in ¥ bn (bars) and net margin in % (line), for the years around the decision. Shaded columns are FY2021 onwards — after it was taken.

Source: securities reports

Read the full dossier in Japanese →

The Japanese edition carries the complete record of this decision — the situation that forced it, the options weighed, what actually followed, and the sources behind every claim.

Other key decisions at Cosmos Pharmaceutical


Yen amounts are converted at the average rate of each figure’s own year — not today’s rate; the revenue chart is shown in yen. Exchange rates & sources — the full ¥/US$ table →


Disclaimer

  • This page is provided for general information only and is not investment advice, nor a recommendation to buy or sell any security.
  • Figures are compiled independently and include our own estimates, approximations and machine-processed data; we make no warranty as to their accuracy or completeness.
  • Sources are primarily each company’s securities reports and other public filings, but errors and omissions may remain.
  • Any use of this information is at the reader’s own risk. Past performance does not indicate future results.
  • Company names, logos and other marks belong to their respective owners.

Data API

Cosmos Pharmaceutical’s history, financials, executives and shareholders are published as static JSON — no key, plain GET. Full specification →

Method Endpoint Returns
GET /api/companies.json All companies
GET /api/3349/manifest.json Resource index
GET /api/3349/history.json History overview
GET /api/3349/timeline.json Chronology
GET /api/decisions.json All management decisions (index)
GET /api/3349/decisions.json Management decisions (index)
GET /api/3349/decisions/{slug}.json One decision (full dossier)
GET /api/3349/executives.json Executives
GET /api/3349/shareholders.json Major shareholders
GET /api/3349/financials.json Financial statements
GET /api/3349/financials-longterm.json Long-term results
GET /api/3349/segments.json Business segments
GET /api/3349/regions.json Sales by region
GET /api/3349/workforce.json Workforce